Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V132 in Healthy Older Participants
NCT07712575Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V132 in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants with Immediate Reactions Occurring Within 30 Minutes After Any Vaccination, Percentage of Participants with a Solicited Injection-site Adverse Event at 7 days and 5 more. Started Aug 2026; status: recruiting.
02
Drugs
V132
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07712575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712575.